Author:
Nicod Elena,Whittal Amanda,Drummond Michael,Facey Karen
Funder
Horizon 2020 Framework Programme
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference38 articles.
1. Godman B, Malmstrom R, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8:77–94.
2. European Commission. Orphan medicinal products. [Cited 2020 Jan 20]. Available from:
https://ec.europa.eu/health/human-use/orphan-medicines_en
.
3. UK Genetic Alliance. Action for access: a report from genetic Alliance UK for the all party parliamentary group on rare, genetic and undiagnosed conditions; 2019.
4. Nicod E, Annemans L, Bucsics A, Lee A, Upadhyaya S, Facey K. HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Health Policy (New York). 2019;123:140–51.
5. Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest group. Value Health. 2018;21:493–500.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献